Original Research

18F-FDG Micro PET/CT imaging to evaluate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity

Weitao Tao a, Siqi Wang b, Alei Xu b, Yangyang Xue b, Hui Wang b, Huiqin Xu a,b,c*

a School of Basic Medical Sciences, Anhui Medical University, No. 81 Meishan Road, Hefei 230032, China
b Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, No. 218 Jiexi Road, Hefei 230022, China

A R T I C L E   I N F O

Keywords:
BRCA1
Breast cancer
Radiosensitivity
Fluorodeoxyglucose
PET/CT

A B S T R A C T

Objective: Radioresistance of tumor cells is a major factor associated with failure of radiotherapy (RT). This study aimed to investigate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity.

Materials and methods: Short hairpin RNA (shRNA) was used to knock down BRCA1 gene in MDA-MB231 cells. Cell viability and proliferative capacity were assessed by CCK-8 and colony formation assays, respectively. We established xenograft models in nude mice to evaluate tumor volume and tumor weight. The mice were imaged by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) before and after RT to evaluate changes in maximum standardized uptake value (SUVmax) and tumor SUVmax/muscle SUVmax (TMR). Changes in HIF-1α, Glut-1 and Ki-67 were analyzed and the correlation between 18F-FDG uptake and tumor biology was analyzed.

Results: Compared with the control cells, RT significantly reduced cell viability and colony formation capacity in cells with the BRCA1 gene knockdown. In vivo assays showed that there was obvious delay in the tumor growth in the shBRCA1 + RT group compared with the control group. 18F-FDG Micro PET/CT indicated a reduction in glucose metabolism in the shBRCA1 + RT group, with statistically significant differences in both the SUVmax and TMR. The data showed the expression of HIF-1α, Glut-1 and Ki-67 was downregulated in the shBRCA1 + RT group, and both SUVmax and TMR had significant correlation with tumor biology.

Conclusion: These results demonstrated that BRCA1 knockdown improves the sensitivity of MDA-MB231 breast cancer cells to RT. In addition, 18F-FDG PET/CT imaging allows non-invasive analysis of tumor biology and assessment of radiosensitivity.

Introduction

Breast cancer accounts for the highest cancer cases in the world, with an estimated 2.3 million cases per year and more than 680,000 deaths [1]. Breast cancer is the second most common cause of death in women, with women aged between 20 and 59 years being most affected [2]. Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks estrogen receptor (ER) or progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [3]. TNBC accounts for about 15% of all breast cancer patients and is highly aggressive, with a very poor prognosis and a five-year mortality rate of 40% [4,5]. Due to lack of specific molecular targets, there is no effective therapeutic option for TNBC.

Women with TNBC often undergo a combination of surgery, chemotherapy, RT and immunotherapy [6,7]. RT is one of the adjuvant treatment options administered following a breast cancer surgery. However, these systemic treatments have poor side effects, leading to higher recurrence rates and shorter overall survival [7,8]. Previous studies have shown that while tumor cells are damaged after receiving RT, the expression of relevant genes changes with changing environment and the tumor cells develop radioresistance. These events increase the incidence of cancer recurrence and metastatic disease, which ultimately lead to reduction or failure of the treatment [9–11].

BRCA1 as a breast cancer susceptibility gene, plays a critical role in DNA homologous recombination repair (HRR) with the RAD51 protein family [12,13]. At the occurrence of DNA damage, BRCA1 combines

Abbreviations: TNBC, Triple negative breast cancer; shRNA, Short hairpin RNA; 18F-FDG, 18F-fluorodeoxyglucose; PET/CT, Positron emission tomography/computed tomography; SUVmax, Maximum standardized uptake value; HRR, Homologous recombination repair.

* Corresponding author at: School of Basic Medical Sciences, Anhui Medical University, No. 81 Meishan Road, Hefei 230032, China.
E-mail address: hfhuiqinxu@163.com (H. Xu).

https://doi.org/10.1016/j.tranon.2022.101517
Received 8 June 2022; Received in revised form 29 July 2022; Accepted 9 August 2022
1936-5233/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
with BRCA1-associated RING domain protein 1 (BARD1) to form tumor suppressor complex BRCA1-BARD1, which recruits RAD51 and BRCA2-PALB2 (a tumor suppressor complex), into the vicinity of double-stranded DNA breaks [14–16]. Some studies have shown that BRCA1 knockdown can lead to significant reduction in HRR efficiency and has little effect on cell cycle distribution [17]. BRCA1 knockdown can lead to significant reduction in HRR efficiency and has little effect on cell cycle distribution [17]. Therefore, since RT leads to DNA damage, silencing the BRCA1 gene does not support the repair damage in breast cancer cells. We hypothesized that BRCA1 gene knockdown could increase the damage caused by RT and improve radiosensitivity in MDA-MB231 cells. Thus, we investigated the effect of silencing the BRCA1 gene in the response of MDA-MB-231 cell lines to RT and then employed $^{18}$F-FDG Micro PET/CT imaging to monitor tumor glucose metabolism in nude mice models of breast cancer.

Materials and methods

Cell culture

Human breast cancer MDA-MB231 cell line was acquired from American Type Culture Collection (ATCC). The cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, USA), with a supplement of 10% fetal bovine serum (FBS; HyClone, USA), 5% penicillin/streptomycin (Gibco, USA) and placed in a 5% CO$_2$ incubator at 37 °C.

Lentivirus-mediated BRCA1 knockdown

Lentiviral shBRCA1 and a negative control lentiviral shRNA (shNC) were designed and synthesized by Hanbio (Shanghai, China). The target shRNA-BRCA1 sequence and the negative control sequence are shown in Table 1. According to the manufacturer’s manual, MDA-MB231 cells were infected with the corresponding lentiviral shRNA at a multiplicity of infection with 20. The addition of 4 μg/ml polybrene to enhance the transfection efficiency. Stable shBRCA1 and shNC cells were selected for at least 3 generations with 2 μg/ml of puromycin.

RT-qPCR analysis

Total RNAs were extracted with Trizol reagent (Invitrogen, USA), and reverse transcribed into cDNA by using PrimeScript TMRT Master Mix kit (TaKaRa, Japan) according to the manufacturer’s manual. RT-qPCR was performed using the SYBR Premix Ex TaqTM II kit (TaKaRa, Japan). Initial denaturation at 95 °C for 30 s, followed by 40 cycles of at 95 °C for 15 s and then 60 °C for 60 s. The cycle threshold (CT) value was defined as the number of PCR cycles in which the fluorescence signal exceeded the detection threshold value. The relative mRNA expression of targeting genes was analyzed by using the formula $2^{-\Delta\Delta CT}$. The pairs of primers are listed in Table 1.

Western blot analysis

Western blot was carried out according to standard methods, as described previously [25]. The primary antibodies used were: mouse anti-BRCA1 antibodies (Santa Cruz, USA), and mouse anti-GAPDH antibodies (Wanleibio, China). Anti-GAPDH antibodies expression was used as loading control. The secondary antibody was Sheep anti-rabbit IgG-HRP (Wanleibio, China). Quantitative analysis of protein expression was performed using Image J software (National Institutes of Health, USA).

CCK-8 assay

The CCK-8 assay was used to assess the cell viability and proliferation. Cells were seeded in 96-well plates at a density of $1 \times 10^3$ cells/well. One day later, the cells were received to 4 Gray (Gy) of radiation. Then CCK-8 reagent (Beyotime, Shanghai, China) was then added to the cell culture medium daily for three days. One hour after CCK-8 addition, the absorbance was measured at a wavelength of 490 nm by a microplate reader (BioTek Instruments, USA). The experiments were independently performed for three times.

Colony formation assay

The cells were seeded in 6-well plates with a density of 500 cells/well. After overnight culture, the cells were exposed to 0, 2, 4, 6 and 8 Gy X-rays at a dose rate of 4 Gy/min. Thereafter, the cells were cultured in a 37 °C incubator for 2 weeks. The colonies were fixed with 4% paraformaldehyde for 30–40 min and then stained with 0.5% crystal violet for 30 min. Colonies with more than 50 cells stained were counted using the Image J software and then survival fraction (SF) was calculated. The cell survival curves were fitted according to the multi-target single-hit model (SF = $1 – (1 – \exp(-D/D_0))N$) and survival enhancement rate (SER) was calculated by acquiring some radiobiological parameters, such as K, N, D$_0$, D$_{37}$, where D is the irradiation dose, K is the

Table 1

| Name  | Sequence (5′–3′) |
|-------|-----------------|
| shNC  | Fw: GATCCGGTTCTCGGAAAGTGTACGTAACATCAAGAGATTGTCAGCATTGAGCTGGGAAGTTTTTTC |
|       | Rw: AATGAAAAATTTCTGGAACGTTGCAATCTCTGGAATTAGGTGACACGGTGAGAGG |
| shBRCA1| Fw: GATCCGGAGCAGAGGGATACATGCAACACTGACTGAGTTGTCTAGTGTAGTACTTCGTCGGTTTGT |
|       | Rw: AATTCGAAAACAGGACAGAGGATACATGCAACACTGACTGAGTTGTCTAGTGTAGTACTTCGTCGGTTTGT |
|       | qFw: GAAAGGCGGTCGGAGAAATAT |
| BRCA1  | qRw: GTTTCACCTTCACAACAGA |
|       | qFw: ACAGTCAGCCGCTATCTCTT |
| GAPDH  | qRw: GACAAGCTCCGTCTTCTCAG |

For: forward primer. Rw: reverse primer. qFw: forward primer for RT-qPCR. qRw: reverse primer for RT-qPCR.
passivation constant of the cell survival curve, \(N\) is the value of the point where the linear portion of the curve extends and intersects the vertical axis (both \(K\) and \(N\) can be obtained directly from the fitted curves). \(D_0\) represents the average lethal dose (\(D_0 = 1/K\)), which is the theoretical amount of radiation energy required to make an average of one hit per cell. \(D_q\) means quasithreshold dose which represents the width of the curve shoulder (\(D_q = D_0 \times \ln N\)), and characterizes the ability to repair sublethal damage. \(D_{37}\) is the corresponding radiation dose at a cell survival fraction of 37% (\(D_{37} = D_0 + D_q\)). The SER\(_{37}\) equation is as follows: \(\text{SER}_{37} = -\text{negative control group } D_0/\text{silencing group } D_0\).

**Xenograft tumor model and treatment**

Four-to five-week-old female BALB/c nude mice (20–25 g), were provided by Beijing Vital River Laboratory Animal Technology. The mice were housed in an environment with a temperature of 26 ± 1 °C relative humidity of 50 ± 1%, and a light/dark cycle of 12/12 h. All the animal experiments were approved by the Ethics Review Committee for Animal Experimentation of Anhui Medical University (No. LLSC20211059). Nude mice were anesthetized with 1% isoflurane-to-air mixture and then injected with 5.0 × 10^6 MDA-MB-231 cells in the right upper limb amput region. Tumors > 10 mm in vernier caliper were selected for subsequent experiments. The nude mice were randomly divided into four groups (\(n = 6/\)group): shNC group; shNC+RT group; shBRCA1 group and shBRCA1+RT group. Nude mice receiving RT were irradiated with VARIAN 23 EX medical linear accelerator (Varian medical System Inc, Palo Alto CA, USA) every other day for one week at a dose of 4 Gy, 4 Gy/min, as shown in Fig. 1.

**Assessment of tumor volume and tumor weight**

The tumor diameters started to be measured when the tumor shapes could be observed. Tumor diameters were measured by vernier caliper once every two days and tumor volume (V) was calculated as \(V = \text{length (cm)} \times \text{width}^2 \times \pi/6\). After the last PET/CT imaging, the animals were euthanized and the tumors were separated and weighed.

**18F-FDG Micro PET/CT imaging and analysis**

Each mouse was scanned using 18F-FDG Micro PET/CT (Siemens, Germany, Small-Animal PET research center of Shanghai Ruijin Hospital) before RT and 24 h after the last RT. The radiochemical purities of 18F-FDG were more than 95%. Each mouse received 5.55 MBq (150μCi) of 18F-FDG through a tail vein injection 60 min before the start of the scan. Isoflurane (1% isoflurane-to-air mixture) was administered before the scan. PET images were reconstructed using the Inveon Acquisition Workplace software (version 2.0, Siemens Preclinical Solutions). On the other hand, the SUV\(_{\text{max}}\) was determined by measuring the maximal concentration of radioactivity in the region of interest (ROI) for semi-quantitative evaluation of 18F-FDG uptake in tumors. The SUV\(_{\text{max}}\) within ROI was calculated using the following formula: concentration of radioactivity in the ROI (MBq/mL) × total body weight (kg)/injected radioactivity (g/MBq). The PET/CT metric for statistical analysis was determined as the tumor tissue SUV\(_{\text{max}}\) (T), the contralateral normal muscle SUV\(_{\text{max}}\) (M), and the ratio of the two values (TMR).

**Pathological assays**

The tumors were harvested and fixed in 4% paraformaldehyde, and then tumor samples were removed and embedded in paraffin. For Hematoxylin and Eosin and immunohistochemical staining, the sections were cut into sections measuring 4 μm in thickness. The tissue sections were then incubated with anti-HIF-1a antibodies (dilution: 1:200, Beyotime Biotechnology, Shanghai, China), anti-Glut-1 antibodies (dilution: 1:300, Beyotime Biotechnology, Shanghai, China) or anti-Ki-67 antibodies (dilution: 1:200, Beyotime Biotechnology, Shanghai, China), followed by horseradish peroxidase-conjugated antirabbit IgG (dilution: 1:200; Beyotime Biotechnology, Shanghai, China). Thereafter, DAB chromogenic kit (Beyotime Biotechnology, Shanghai, China) was used to stain and visualize the positive cells.

The data were analyzed using the Image-Pro-Plus 6.0 software (Media Cybernetics, USA). The integrated optical density (IOD) was employed to evaluate the area and intensity of the positive staining. The IOD of all positive stains was obtained from selected areas in each section, and the results were expressed as mean density = Sum (IOD)/Sum (Area). All the section under immunohistochemical staining were assessed by at least two observers.

**Statistical analysis**

All data were expressed as mean ± standard deviation (SD). Statistical analysis was performed using SPSS 26.0 (Armonk, USA) and GraphPad Prism 8.3 Software (San Diego, USA). The comparison between two groups was analyzed by independent-samples \(t\)-test or paired-sample \(t\)-test, the comparison among multiple groups was analyzed by one-way ANOVA analysis and with the LSD post hoc test. The association of 18F-FDG uptake with HIF-1a, Glut-1 and Ki-67 were assessed by Pearson correlation analysis. \(P < 0.05\) was considered statistically significant.

**Results**

**Lentivirus-mediated BRCA1 knockdown in MDA-MB231 cells**

We successfully generated stable BRCA1 knockdown MDA-MB231 breast cancer cells using a lentivirus-mediated system. Our western blot and RT-qPCR analyses showed that the levels of BRCA1 protein and mRNA expression were significantly lower in the BRCA1 knockdown

---

**Fig. 1.** Outline of tumor implantation, RT, and imaging schedule (Day 1 is the tumor cells implantation day).
cells compared with matched shNC group cells (both $P < 0.001$) (Fig. 2A-C).

Effects of silencing BRCA1 on proliferation in vitro

The effects of RT on cell proliferation capacity and viability in the BRCA1 knock down cells were examined by the CCK-8 and colony formation assays. As shown in Fig. 2D-G, RT reduced cell viability and

Fig. 2. Effect of silencing BRCA1 gene on cell viability and proliferation in vitro experiments. Control group: no transduction; shNC group: breast cell lines stably transduced with negative control lentiviral shRNA; shBRCA1 group: breast cell lines stably transduced with lentivirus-mediated BRCA1 shRNA. (A) BRCA1 protein expression was analyzed by western blotting with GAPDH as a control. (B) Western blotting results of the three groups of cells were represented by quantitative graphs. (C) BRCA1 mRNA was determined by RT-qPCR. (D) Changes in OD$_{490nm}$ values of cells in shNC and shBRCA1 group at 24 h, 48 h and 72 h after 4 Gy irradiation. (E) Cell viability of cells in shNC and shBRCA1 group at 48 h after 0 or 4 Gy irradiation. (F) Survival curve was fitted according to the multi-target single-hit model. (G) Representative images of respective colony formation in two groups of cells at different doses ($0, 2, 4, 6$, and $8$ Gy). Data are shown as mean ± standard deviation (SD) from three independent experiments. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$, vs. shNC group or shBRCA1 group; ##$P < 0.01$, ###$P < 0.001$ vs. shNC + RT group.
were highly expressed in tumor tissues, and the mean density of HIF-1α, Glut-1 and Ki-67 was significantly suppressed in both groups receiving RT. In the shBRCA1 + RT group, the mean density of HIF-1α, Glut-1 and Ki-67 expression was shown to be 25.50%, 22.82% and 54.42% for each group.

Table 2
Summary of radiobiological parameters.

| Group       | N  | D0 | D2 | D4 | D27 | SER57 |
|-------------|----|----|----|----|-----|-------|
| shNC        | 0.41 | 3.86 | 2.42 | 3.27 | 5.69 | –     |
| shBRCA1     | 0.58 | 4.09 | 1.72 | 2.42 | 4.14 | 1.41  |

K is the passivation constant of the cell survival curve. N is the value of the point where the linear portion of the curve extends and intersects the vertical axis. D0 represents the average lethal dose (D0 = 1/K), it’s the theoretical amount of radiation energy required to make an average of one hit per cell. D2 means quasithreshold dose represents the width of the curve shoulder (D2 = D0 × ln N), which characterizes the ability to repair sublethal damage. Dα means dose [Gy] to reduce survival fraction to 37% (Dα = D0 + D4). SER57 = D0 (shNC)/D0 (shBRCA1). The SER greater than 1.20 indicate radiosensitization.

Discussion

RT is an essential treatment option for breast cancer, which has been shown to reduce the rate of recurrence and the risk of death. Adjuvant RT after breast-conserving surgery, or in early-stage breast cancer and lymphatic involvement has been widely accepted for breast cancer treatment [26,27]. However, there are still many patients who are threatened by relapse and even death. In many tumor types, recurrence has been associated with acquired radioresistance [28]. A previous randomized clinical trial showed that RT did not reduce death from any reason in any breast cancer subtype [29]. Thus, radioresistance presents a formidable clinical challenge in the systematic treatment of breast cancer. Many studies have extensively evaluated many genes that are associated with tumor radiosensitivity. For example, the role of the apoptosis gene Btg1 [30], HRR gene RAD51 [31] and cell hypoxia-associated gene HIF-1α in radiosensitivity has been defined [32]. However, the role of BRCA1 in response to radiotherapy in breast cancer is poorly understood. Therefore, we investigated the relationship between BRCA1 and radiosensitivity, which is a critical gene in the HRR process. In this study, shRNA-BRCA1 was introduced into the MDA-MB231 cells with the help of lentivirus vector, and was successfully integrated into the genome of the MDA-MB231 cells after infection, thus achieving stable and long term expression.

Our CCK-8 assay demonstrated that the BRCA1 knockdown significantly reduced cell viability after irradiation with 4 Gy and the cell viability was still poor at 48 h and 72 h after RT. In the colony formation assay, we showed that the cell survival rate of the shBRCA1 group was significantly lower than that of the shNC group. BRCA1 gene knockdown suppressed the colony formation in the MDA-MB231 cells with a SER57 of 1.41. These data show that BRCA1 gene knockdown increased the sensitivity of the MDA-MB231 cells to RT. In summary, RT had a higher effect in inhibiting cell proliferation and promoting cell death in BRCA1 knockdown cells with, indicating that BRCA1 knockdown can enhance the sensitivity of tumor cells to radiation.

Previous evidence showed that BRCA1, a major breast cancer suppressor gene, plays an important role in regulating genome stability and DNA repair based on HRR as well as in the repair of DNA double-strand breaks to maintain the fidelity of the genome [33,34]. Yinghua Zhu et al. demonstrated that reduction of the BRCA1 expression with P38K inhibitors restored tamoxifen resistance and sensitivity to cisplatin in breast cancer cells [35]. The use of PARP inhibitors and cisplatin has been shown to prolong overall survival and progression-free survival in breast cancer patients with BRCA1/2-mutated or HRR-deficiency [36,37]. In this study, we successfully silenced BRCA1 gene expression using a lentiviral shRNA approach in MDA-MB231 cells, making the cells to produce HRR-deficiency. Radiation causes DNA strand damage in tumors, and BRCA1 knockdown can inhibit the DNA damage repair process by a series of DNA repair proteins. This suggests that silencing BRCA1 gene plays a role in radiosensitization of tumor cells.

Hypoxia is a typical feature in most solid tumors [38]. Hypoxia and increased HIF-1α activity within the tumor are associated with tumor recurrence and distant metastasis, as well as poor prognosis after radiotherapy. In the early stages of tumor formation, the tumor is often in a hypoxic environment due to the rapid rate of angiogenesis, which stimulates the release of HIFs. The hypoxic microenvironment of solid...
Fig. 3. 18F-FDG Micro PET/CT imaging of tumor xenografts from BALB/c nude mice treated with RT. The BALB/c nude mice were randomly divided into four groups (n = 6/group). (A) Representative coronal 18F-FDG Micro PET/CT images of tumors from different groups of mice at day 14 and day 22. Tumors are indicated by white arrows. (B) Tumor volume (cm³) was assessed every 2 days. (C) Tumor weight (g) was assessed for different groups of mice after 4 times RT. (D) Quantification of SUV_{max} and TMR values of tumors from different groups of mice. Data are shown as mean ± SD (n = 6/group). *P < 0.05, **P < 0.01, ***P < 0.001, vs. shNC group, shBRCA1 group or day 14; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. shNC + RT group.
tumors reduces the sensitivity of the tumor to chemo-radiotherapy, thus increasing the risk of tumor recurrence and metastasis [39]. HIF-1α promotes the growth of endothelial cells after radiotherapy by inducing the expression of crucial downstream genes, which include Glut-1, and thus promoting tumor resistance to radiotherapy. Ki-67, is a marker of cell proliferation, and is important in evaluating the prognosis of early-stage breast cancer, guiding chemotherapy, predicting the effect of chemotherapy, and in neoadjuvant chemotherapy. This study showed that the use of RT in BRCA1 knockdown cells significantly improves the tumor hypoxic microenvironment by downregulating the expression level of HIF-1α, Glut-1 and Ki-67 genes.

18F-FDG is a common imaging agent used to detect the degree of aggressiveness of malignant tumors. The 18F-FDG PET/CT imaging, as a radionuclide imaging technique, has been widely used in the clinic and

|                | SUV\textsubscript{max} Pre-RT | SUV\textsubscript{max} Post-RT | P-value | TMR Pre-RT | TMR Post-RT | P-value |
|----------------|-----------------------------|-----------------------------|---------|------------|------------|---------|
| shNC           | 1.53 ± 0.40                | 1.92 ± 0.43                | 0.019   | 0.11       | 0.30       | 0.001   |
| shNC+RT        | 1.52 ± 0.37                | 2.27 ± 0.40                | 0.002   | 0.15       | 0.27       | 0.008   |
| shBRCA1        | 1.49 ± 0.37                | 2.03 ± 0.37                | 0.03    | 0.37       | 0.24       | 0.008   |
| shBRCA1+RT     | 1.47 ± 0.67                | 2.08 ± 0.37                | 0.005   | 0.31       | 0.10       | 0.001   |

Fig. 4. The effect of knockdown of BRCA1 gene combined with RT on tumor biomarkers. (A) Pathological analysis the Hematoxylin and Eosin staining and the expression of HIF-1α, Glut-1 and Ki-67 in tumors (magnification = 40 ×). (B) Quantification of immunohistochemical analysis using mean density. Data are shown as mean ± SD (n = 6/group). **P < 0.01, ***P < 0.001, vs. shNC group or shBRCA1 group; #P < 0.01, ###P < 0.001 vs. shNC + RT group.
A previous meta-analysis [40] showed a significant effect of $^{18}$F-FDG PET/CT on the staging and treatment of breast cancer patients, resulting in benefits from locally aggressive therapies and prolonged survival. Both SUV$_{\text{max}}$ and TMR can be used as prognostic factors in various malignancies, and a previous study [41] has showed a significant correlation between high SUV$_{\text{max}}$ and poor prognosis in breast cancer patients. Indeed, this is the first study to use $^{18}$F-FDG Micro PET/CT imaging to evaluate tumor growth metabolism after RT in nude mice model of BRCA1-silenced breast cancer cells. In the vivo experiments, we generated a mice model of breast cancer by injecting cells in the right upper limb armpit region of nude mice. This was because of the nature of the imaging readout, which did not choose a more appropriate orthotopic method. The PET/CT imaging results showed that tumors that did not receive RT had higher $^{18}$F-FDG uptake on day 22, while the uptake was reduced to different degrees in those groups which underwent RT. TMR and SUV$_{\text{max}}$ were particularly reduced in the shBRCA1+RT group, a finding consistent with the low expression of HIF-1$\alpha$, Glut-1 and Ki-67. These data show that the use of RT in cells with BRCA1 knockdown significantly improved glucose metabolism in breast tumors. Besides, this data was in sync with the findings that this group had slower tumor volume growth and had lighter tumor weight. The expression of HIF-1$\alpha$, Glut-1 and Ki-67 correlated significantly with the $^{18}$F-FDG uptake, which agreed with the findings of Bravata et al. [42–44]. Together, these results suggested that RT can largely inhibit the growth of tumor tissues with a radiosensitizing effect in BRCA1 knockdown group, and this change can be dynamically monitored and assessed by the $^{18}$F-FDG PET/CT imaging.

These findings may not only provide new research direction to overcome breast cancer radioresistance, but also that BRCA1 may be a new therapeutic target for TNBC by increasing the sensitivity to RT. Several studies [45–48] have demonstrated the value of gene therapy combined with nuclear medicine imaging in tumor imaging and treatment. However, further researches need to be explored in the future about how to prepare a novel positron emitter-labeled short interfering (siRNA) or shRNA, and real-time analysis of siRNA or shRNA trafficking was performed by using PET imaging to provide new approaches for clinical breast cancer imaging, diagnosis, and treatment.

We have some limitations on this study. For example, we didn’t investigate the effect of RT on BRCA1 knockdown breast cancer cells at a more molecular level. Some studies on protein expression during HRR and signaling pathways. In this study, only one type of TNBC cell line was used, and the effects of radiosensitivity on other breast cancer cell lines need to be studied to confirm our experimental results. Further research is needed to confirm the findings and define molecular mechanisms underlying the effect of RT on BRCA1 knockdown breast cancer cells.

**Conclusion**

Overall, our analyses demonstrate that BRCA1 gene knockdown enhances the radiosensitivity of MDA-MB231 breast cancer cells and can downregulate multiple biomarkers of poor prognosis, which may be a novel approach to be used in improving the efficacy of RT. $^{18}$F-FDG PET/CT imaging allows non-invasive acquisition of tumor biology and radiosensitization response assessment.

**CRediT authorship contribution statement**

Weitao Tao: Conceptualization, Methodology, Writing – original draft. Siqi Wang: Software, Data curation. Alei Xu: Software, Data curation. Yangyang Xue: Software, Data curation. Hui Wang: Writing – review & editing. Huiqin Xu: Writing – review & editing.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments

We are grateful to the Department of Nuclear Medicine of Ruijin Hospital affiliated to Shanghai Jiaotong University for providing laboratory support, Micro PET/CT and 18F-FDG for animal imaging. This work was supported by the National Natural Science Foundation of China (No. 81971643).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.tranon.2022.101517.

References

[1] H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, J.W.M. Martens, J. Bussink, F. Sweep, P. Ferlay, J. GStation, Globocan 2018, IARC, Lyon, France.
[2] R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2021, CA Cancer J. Clin. 71 (1) (2021) 209–249.
[3] B. Bhattacharya, M.F. Mohd Omar, R. Soong, The Warburg effect and drug resistance, Br. J. Pharmacol. 173 (6) (2016) 970–979.
[4] W. Warburg, On the origin of cancer cells, Science 123 (1956) 309–314.

[18] F. Huang, A.V. Mazin, A small molecule inhibitor of human RAD51 potentiates miR-155 in breast cancer through RAD51 targeting impairs homologous recombination, Mol. Oncol. 14 (1) (2020) 959.
[19] A. Recht, E.A. Comen, R.E. Fine, G.F. Fleming, P.H. Hardenbergh, A.Y. Ho, C. A. Hudis, E.S. Hwang, J.J. Kirshner, M. Monroe, K.E. Salerno, G.W. Sledge Jr., L. J. Solin, P.A. Spears, T.J. Whelan, M.R. Somerfield, S.B. Edge, Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation oncology, and society of surgical oncology focused guideline update, J. Clin. Oncol. 34 (36) (2016) 4431–4442.
[20] M. Jurikova, L. Daniehl, S. Polak, I. Varga, K67, PCNA, and MCM markers: predictors of proliferation in the diagnosis of breast cancer, Acta Histochem. 118 (5) (2016) 544–552.
[21] R. Hong, W. Zhang, X. Xia, K. Zhang, W. Yang, M. Wu, J. Fan, J. Li, W. Xie, F. Xu, J. Chen, S. Wang, Q. Zhang, Preventing BRCA1/ZBRK1 repressor complex binding to the G0/T2 promoter results in accelerated apurinate biosynthesis and promotion of cell proliferation, Mol. Oncol. 14 (2) (2020) 1529
[22] J.T. Zhong, Q. Yu, S.H. Zhou, E. Yu, Y.Y. Bao, Z.J. Lu, J. Fan, GLUT-1 srNA enhances radiosensitization of laryngeal cancer stem cells via enhanced DNA damage, cell cycle redistribution, and promotion of apoptosis in vitro and in vivo, Radiat. Oncol. Targets Ther. 9 (2020) 105–112.
[23] M. Jurikova, L. Daniehl, S. Polak, I. Varga, K67, PCNA, and MCM markers: predictors of proliferation in the diagnosis of breast cancer, Acta Histochem. 118 (5) (2016) 544–552.
[24] R. Hong, W. Zhang, X. Xia, K. Zhang, W. Yang, M. Wu, J. Fan, J. Li, W. Xie, F. Xu, J. Chen, S. Wang, Q. Zhang, Preventing BRCA1/ZBRK1 repressor complex binding to the G0/T2 promoter results in accelerated apurinate biosynthesis and promotion of cell proliferation, Mol. Oncol. 14 (2) (2020) 1529
[25] A. Jurikova, L. Daniehl, S. Polak, I. Varga, K67, PCNA, and MCM markers: predictors of proliferation in the diagnosis of breast cancer, Acta Histochem. 118 (5) (2016) 544–552.
[26] Y.S. Ko, T. Rugira, H. Jin, Y.N. Hoo, H.J. Kim, Radiotherapy-resistant breast cancer cells enhance tumor progression by enhancing premetastatic niche formation through the HIF-1a/LamdaCh fractalkine/MCP-1 axis, Int. J. Mol. Sci. 21 (2020) 7097–7113.
[27] J.T. Zhong, Q. Yu, S.H. Zhou, E. Yu, Y.Y. Bao, Z.J. Lu, J. Fan, GLUT-1 srNA enhances radiosensitization of laryngeal cancer stem cells via enhanced DNA damage, cell cycle redistribution, and promotion of apoptosis in vitro and in vivo, Radiat. Oncol. Targets Ther. 9 (2020) 105–112.
[28] J. Solin, P.A. Spears, T.J. Whelan, M.R. Somerfield, S.B. Edge, Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation oncology, and society of surgical oncology focused guideline update, J. Clin. Oncol. 34 (36) (2016) 4431–4442.
[29] M.E.J. Stouthaifeld, F. Kayser, V. Vakae, R. Khoury, P. Deseyne, C. Monten, J. Abraham, S. Barrett, P. Barrett-Lee, R. Brown, S. Chan, M. Dowsett, J. Solin, P.A. Spears, T.J. Whelan, M.R. Somerfield, S.B. Edge, Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation oncology, and society of surgical oncology focused guideline update, J. Clin. Oncol. 34 (36) (2016) 4431–4442.
[30] M.J. Lebert, R. Lester, E. Powell, M. Seal, J. McCarthy, Advances in the systemic treatment of triple-negative breast cancer, Curr. Oncol. 25 (Suppl 1) (2018) 1–10.
[31] C. Denkert, C. Liedtke, A. Tutt, G. von Minckwitz, Molecular alterations in triple-negative breast cancer: challenges and opportunities of a heterogeneous disease, Nat. Rev. Clin. Oncol. 11 (13) (2014) 674–690.
[32] A.G. Waks, E.P. Winer, Breast cancer treatment: a review, JAMA 321 (3) (2019) 288–300.
[33] J.M. Lebert, R. Lester, E. Powell, M. Seal, J. McCarthy, Advances in the systemic treatment of triple-negative breast cancer, Curr. Oncol. 25 (Suppl 1) (2018)
[34] W. Tao et al.
[35] S. Al-Mahmood, J. Sapienza, O.B. Garbuzevko, T. Minko, Metastatic and triple-negative breast cancer: challenges and treatment options, Drug Deliv. Transl. Res. 8 (5) (2018) 1485–1507.
[36] A. Lee, M.B.A. Djamous, Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies, Cancer Treat. Rev. 62 (2018) 110–122.
[37] S. Siwko, R. Hu, J.S. Lee, B. Hennessy, S. Hanash, G.B. Mills, S.Y. Lin, Genome-wide transcriptome profiling of homologous recombination DNA repair, Nat. Commun. 5 (2014) 3361.
[38] Y. Xiong, G.M. Kupfer, C. Wiese, E.C. Greene, P. Sung, BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing, Nature 550 (7676) (2017) 360–314.
[39] M. Romeo, J.C. Pardo, A. Martinez-Cardus, E. Martinez-Balibrea, V. Quiroga, and replication complex I, DNA Repair (Amst.) 97 (2014) 552–579.
[40] A. Tutt, H. Tovey, M.C.U. Cheang, S. Kernaghan, L. Kilburn, P. Gazinska, J. Owen, J. Chen, S. Wang, Q. Mo, S. Siwko, R. Hu, J.S. Lee, B. Hennessy, S. Hanash, G.B. Mills, S.Y. Lin, Genome-wide transcriptome profiling of homologous recombination DNA repair, Nat. Commun. 5 (2014) 3361.
[41] J. Chen, S. Wang, Q. Mo, S. Siwko, R. Hu, J.S. Lee, B. Hennessy, S. Hanash, G.B. Mills, S.Y. Lin, Genome-wide transcriptome profiling of homologous recombination DNA repair, Nat. Commun. 5 (2014) 3361.
[42] J. Chen, S. Wang, Q. Mo, S. Siwko, R. Hu, J.S. Lee, B. Hennessy, S. Hanash, G.B. Mills, S.Y. Lin, Genome-wide transcriptome profiling of homologous recombination DNA repair, Nat. Commun. 5 (2014) 3361.
[43] H.W. Kwon, J.H. Lee, K. Pahk, K.H. Park, S. Kim, Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism information, J. Clin. Oncol. 35 (28) (2017) 3222–3229.
[44] D. Jing, S. Azghadi, W. Zhou, L. Liu, N. Jiang, T. Li, T. Gao, C. Sweeney, R. Shen, T. Yin, L. C. Tan, F. Sweep, P. Ferlay, J. GStation, Globocan 2018, IARC, Lyon, France.
characteristics measured using FDG PET/CT, Cancer imaging: the official publication of the International, Cancer Imaging Soc. 21 (1) (2021) 55.

[45] R. Juliano, M.R. Alam, V. Dixit, H. Kang, Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides, Nucleic Acids Res. 36 (12) (2008) 4158–4171.

[46] F. Mercier, J. Paris, G. Kaisin, D. Thonon, J. Flagothier, N. Teller, C. Lemaire, A. Luxen, General method for labeling siRNA by click chemistry with fluorine-18 for the purpose of PET imaging, Bioconjug. Chem. 22 (1) (2011) 108–114.

[47] H. Mukai, K. Hatanaka, N. Yagi, S. Warashina, M. Zouda, M. Takahashi, K. Narashima, H. Yabashi, J. Iwano, T. Kuboyama, J. Enokizono, Y. Wada, Y. Watanabe, Pharmacokinetic evaluation of liposomal nanoparticle-encapsulated nucleic acid drug: a combined study of dynamic PET imaging and LC/MS/MS analysis, J. Control Rel. 294 (2019) 185–194.

[48] K. Hatanaka, T. Asai, H. Koide, E. Kenjo, T. Tsuzuki, N. Harada, H. Tsukada, N. Oka, Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography, Bioconjug. Chem. 21 (4) (2010) 756–763.